Heidelberg Pharma is a German-listed company with a focus on oncology. It is the only company in the antibody-drug conjugate (ADC) space listed in Europe.

Heidelberg Pharma is developing ADCs based on the novel toxic payload Amanitin, through its proprietary Antibody Targeted Amanitin Conjugate technology (ATAC). This has a breakthrough mode of action: Amanitin kills both dividing and dormant tumor cells, potentially preventing cancer relapse. It has shown to be more effective in tumors with 17p deletion, a biomarker of disease severity that could help identify high-risk patients.

Heidelberg Pharma’s lead product HDP101 is about to start a Phase I/IIa clinical study. This is complemented by a proprietary preclinical product portfolio with different antibody backbones and by partnered products that are expected to generate short-term revenues.

The Follow-on Offering proceeds will be used to finance:
• Phase I/II trials for the HDP101 investigational therapy
• R&D and general & administrative expenses up to June 2022
• Finalizing the preclinical package and Good Manufacturing Practice (GMP) materials
• Investigational New Drug (IND) application filing for the HDP102 and HDP103 treatments in H1 2022.

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. It is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the company’s proprietary Antibody Targeted Amanitin Conjugate technology (ATAC) as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma and will enter clinical development shortly. HDP-102, a CD37 ATAC for Non-Hodgkin’s lymphoma and HDP-103, a PSMA ATAC for metastatic castration-resistant prostate cancer, are in preclinical testing.

Discover Heidelberg Pharma

Hervé Ronin

Investment Banking

Hervé Ronin photo

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Sandrine Cailleteau

Investment Banking

Sandrine Cailleteau photo

Daniel Rayot

Investment Banking

Daniel Rayot photo

Cosme Rosellini

Equity Capital Markets

Cosme Rosellini photo

Martin Piehlmeier

Investment Banking

Martin Piehlmeier photo

Théodore de Charsonville

Equity Capital Markets

Théodore De Charsonville photo

Privacy Preference Center

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }